The physiology of proinsulin c-peptide: Unanswered questions and a proposed model

Physiology

Volumn 30, Issue 4, 2015, Pages 327-332

  Yosten, Gina L C ^a   Kolar, Grant R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; G PROTEIN COUPLED RECEPTOR; INSULIN;

ANIMAL; BIOLOGICAL MODEL; DIABETIC ANGIOPATHY; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; C-PEPTIDE; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84936098144     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00008.2015     Document Type: Article

References (54)

1. Bhatt MP, Lim YC, Hwang J, Na S, Kim YM, Ha KS. C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes62: 243–253, 2013.
2. Bhatt MP, Lim YC, Kim YM, Ha KS. C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes62: 3851–3862, 2013.
3. Bo S, Gentile L, Castiglione A, Prandi V, Canil S, Ghigo E, Ciccone G. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol167: 173–180, 2012.
4. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol6: a009191, 2014.
5. Chini B, Manning M. Agonist selectivity in the oxytocin/ vasopressin receptor family: new insights and challenges. Biochem Soc Trans35: 737–741, 2007.
6. Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia54: 2702–2712, 2011.
7. Davidson HW. (Pro)Insulin processing: a historical perspective. Cell Biochem Biophys 40: 143–158, 2004.
8. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by Cpeptide in patients with type 1 diabetes. Diabetes52: 536–541, 2003.
9. Ellsworth ML, Sprague RS. Regulation of blood flow distribution in skeletal muscle: role of erythrocyte-released ATP. J Physiol590: 4985–4991, 2012.
10. Faber OK, Kehlet H, Madsbad S, Binder C. Kinetics of human C-peptide in man. Diabetes 27, Suppl 1: 207–209, 1978.
11. Flatt PR, Swanston-Flatt SK, Hampton SM, Bailey CJ, Marks V. Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor. Biosci Rep6: 193–199, 1986.
12. Forst T, Rave K, Pfuetzner A, Buchholz R, Pohlmann T, Lobig M, Heinemann L. Effect of C-peptide on glucose metabolism in patients with type 1 diabetes. Diabetes Care25: 1096–1097, 2002.
13. Giebink AW, Vogel PA, Medawala W, Spence DM. C-peptide-stimulated nitric oxide production in a cultured pulmonary artery endothelium is erythrocyte mediated and requires Zn2_. Diabetes Metab Res Rev29: 44–52, 2013.
14. Grunberger G, Qiang X, Li Z, Mathews ST, Sbrissa D, Shisheva A, Sima AA. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia44: 1247–1257, 2001.
15. Haidet J, Cifarelli V, Trucco M, Luppi P. C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia. Inflam Res61: 27–35, 2012.
16. Henriksson M, Pramanik A, Shafqat J, Zhong Z, Tally M, Ekberg K, Wahren J, Rigler R, Johansson J, Jornvall H. Specific binding of proinsulin Cpeptide to intact and to detergent-solubilized human skin fibroblasts. Biochem Biophys Res Commun280: 423–427, 2001.
17. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein- coupled receptors. Pharmacol Therap99: 25–44, 2003.
18. Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Clin Sci116: 565–574, 2009.
19. Hills CE, Brunskill NJ. Intracellular signalling by C-peptide. Exp Diabetes Res2008: 635158, 2008.
20. Hills CE, Brunskill NJ, Squires PE. C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol31: 389–397, 2010.
21. Hutton JC. Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases. Diabetologia 37, Suppl 2: S48–S56, 1994.
22. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science277: 563–566, 1997.
23. Ishii T, Fukano K, Shimada K, Kamikawa A, Okamatsu- Ogura Y, Terao A, Yoshida T, Saito M, Kimura K. Proinsulin C-peptide activates alphaenolase: implications for C-peptide: cell membrane interaction. J Biochem152: 53–62, 2012.
24. Jagerbrink T, Lindahl E, Shafqat J, Jornvall H. Proinsulin C-peptide interaction with protein tyrosine phosphatase 1B demonstrated with a labeling reaction. Biochem Biophys Res Commun387: 31–35, 2009.
25. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med17: 181–189, 2000.
26. Kitamura T, Kimura K, Jung BD, Makondo K, Okamoto S, Canas X, Sakane N, Yoshida T, Saito M. Proinsulin C-peptide rapidly stimulates mitogen- activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxinsensitive G-protein. Biochem J355: 123–129, 2001.
27. Lachin JM, McGee P, Palmer JP. Impact of Cpeptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes63: 739–748, 2014.
28. Lee S, Lynn EG, Kim JA, Quon MJ. Protein kinase C-zeta phosphorylates insulin receptor substrate- 1, -3, and -4 but not -2: isoform specific determinants of specificity in insulin signaling. Endocrinology149: 2451–2458, 2008.
29. Li Y, Zhao M, Li B, Qi J. Dynamic localization and functional implications of C-peptide might for suppression of iNOS in high glucose-stimulated rat mesangial cells. Mol Cell Endocrinol381: 255–260, 2013.
30. Lim YC, Bhatt MP, Kwon MH, Park D, Lee S, Choe J, Hwang J, Kim YM, Ha KS. Prevention of VEGFmediated microvascular permeability by C-peptide in diabetic mice. Cardiovasc Res101: 155–164, 2014.
31. Lim YC, Bhatt MP, Kwon MH, Park D, Na S, Kim YM, Ha KS. Proinsulin C-peptide prevents impaired wound healing by activating angiogenesis in diabetes. J Invest Dermatol135: 269–278, 2015.
32. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia51: 1534–1543, 2008.
33. Luppi P, Cifarelli V, Wahren J. C-peptide and long-term complications of diabetes. Pediatr Diabetes12: 276–292, 2011.
34. Luppi P, Geng X, Cifarelli V, Drain P, Trucco M. C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia52: 2218–2228, 2009.
35. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grub M, Hombach V, Libby P, Zieske A, Homma S, Strong J. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol24: 540–545, 2004.
36. Pietropaolo M. Persistent C-peptide: what does it mean? Curr Opin Endocrinol Diabetes Obes20: 279–284, 2013.
37. Pramanik A, Ekberg K, Zhong Z, Shafqat J, Henriksson M, Jansson O, Tibell A, Tally M, Wahren J, Jornvall H, Rigler R, Johansson J. C-peptide binding to human cell membranes: importance of Glu27. Biochem Biophys Res Commun284: 94–98, 2001.
38. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun389: 211–216, 2009.
39. Richards JP, Bowles EA, Gordon WR, Ellsworth ML, Stephenson AH. Mechanisms of C-peptidemediated rescue of low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol308: R411–R418, 2015.
40. Richards JP, Stephenson AH, Ellsworth ML, Sprague RS. Synergistic effects of C-peptide and insulin on low O2-induced ATP release from human erythrocytes. Am J Physiol Regul Integr Comp Physiol305: R1331–R1336, 2013.
41. Richards JP, Yosten GL, Kolar GR, Jones CW, Stephenson AH, Ellsworth ML, Sprague RS. Low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes is restored by physiological ratios of C-peptide and insulin. Am J Physiol Regul Integr Comp Physiol307: R862–R868, 2014.
42. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren P, Stahl S, Ekberg K, Johansson B, Uhlen S, Uhlen M, Jornvall H, Wahren J. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA96: 13318–13323, 1999.
43. Scalia R, Coyle KM, Levine BJ, Booth G, Lefer AM. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J14: 2357–2364, 2000.
44. Strunecka A, Hynie S, Klenerova V. Role of oxytocin/ oxytocin receptor system in regulation of cell growth and neoplastic processes. Folia Biol (Krakow)55: 159–165, 2009.
45. Tsimaratos M, Roger F, Chabardes D, Mordasini D, Hasler U, Doucet A, Martin PY, Feraille E. C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia46: 124–131, 2003.
46. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in Type 1 diabetes. Diabetes61: 761–772, 2012.
47. Wahren J, Larsson C. C-peptide: new findings and therapeutic possibilities. Diabetes Res Clin Pract107: 309–319, 2015.
48. Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes53: 1664–1670, 2004.
49. Wallerath T, Kunt T, Forst T, Closs EI, Lehmann R, Flohr T, Gabriel M, Schafer D, Gopfert A, Pfutzner A, Beyer J, Forstermann U. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide9: 95–102, 2003.
50. Wu J, Xie N, Zhao X, Nice EC, Huang C. Dissection of aberrant GPCR signaling in tumorigenesis– a systems biology approach. Cancer Genomics Proteomics9: 37–50, 2012.
51. Yosten GL, Kolar GR, Redlinger LJ, Samson WK. Evidence for an interaction between proinsulin C-peptide and GPR146. J Endocrinol218: B1–B8, 2013.
52. Yosten GL, Maric-Bilkan C, Luppi P, Wahren J. Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab307: E955–E968, 2014.
53. Yosten GL, Redlinger LJ, Samson WK. Evidence for an interaction of neuronostatin with the orphan G protein-coupled receptor, GPR107. Am J Physiol Regul Integr Comp Physiol303: R941–R949, 2012.
54. Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF. Severe block in processing of proinsulin to insulin accompanied by elevation of des- 64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci USA99: 10299–10304, 2002.